KyDo Therapeutics extends €4.45M seed as insiders back cancer drug platform
What's the deal? KyDo TherapeuticsDealroom has a profile for this one. Try Dealroom →, a preclinical-stage biotech in Dortmund, Germany, has raised a seed extension from existing investors to advance its covalent-allosteric oncology platform. The backers include i&i Biotech FundDealroom has a profile for this one. Try Dealroom →, KHAN Technology Transfer Fund II, VORNvcDealroom has a profile for this one. Try Dealroom →, TU capitalDealroom has a profile for this one. Try Dealroom →, and Lead Discovery CenterDealroom has a profile for this one. Try Dealroom →, alongside the company's management and founders. KyDo did not disclose the amount.
Why now? The financing follows new preclinical data on KyDo's lead program. It extends a €4.45 million seed round led by i&i Biotech Fund that closed in September 2025.
What's the endgame? KyDo develops small-molecule inhibitors for genetically defined cancers, combining covalent binding with allosteric target modulation to overcome drug resistance. The new money will push its lead program towards development-candidate nomination while characterising its proprietary compounds.
"The latest data have further strengthened our conviction that our covalent-allosteric approach may offer a differentiated opportunity to address important limitations of current targeted cancer therapies," said chief executive officer Matthias Stein-Gerlach.
KyDo was founded by Lead Discovery CenterDealroom has a profile for this one. Try Dealroom → and scientists from TU Dortmund University's Rauh Lab. It won the 2026 MATWIN prize for the best drug-based innovation project in oncology.
What could go wrong? KyDo disclosed neither the amount raised nor detailed preclinical results, limiting any assessment of the round's scientific or financial weight. The company says it will keep engaging investors and partners as it builds a data package for future funding.
The signal: Dortmund's life sciences scene is growing, and German oncology startups have drawn bigger seed rounds this year — iDEL TherapeuticsDealroom has a profile for this one. Try Dealroom → raised €9 million in March, and Cologne-based DISCO Pharmaceuticals announced a €20 million seed in November. Against that backdrop, KyDo's insider-backed follow-on is a modest bridge whose significance rests on whether later data validate the program.
Read more: life-sciences-europe.com
Image credit: Generated with Gemini
